National Expert Group meets Covid-19 vaccine makers to discuss road ahead
Representatives from Serum Institute of India, Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals and Biological E met the expert group that is chaired by NITI member Vinod K Paul Expert group on Covid-19 vaccine to meet vaccine-makers on Tuesday
Serum Institute, Bharat Bio and Zydus Cadila among others to attend CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from the USFDA for Sevelamer Carbonate Tablets CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches RemdacTM (Remdesivir) for the treatment of COVID 19 in India Earnings Call Transcript - Q1FY21 for Cadila Healthcare
Conference Call between Cadila Healthcare Management and Analysts on Q1FY21 performance and outlook. Click on pdf for full transcript.
Sell Cadila Healthcare; target of Rs 329: Prabhudas Lilladher
Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 329 in its research report dated August 06, 2020.
Hold Cadila Healthcare; target of Rs 445: Sharekhan
Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 445 in its research report dated August 05, 2020. Cadila Healthcare stock slips post Q1 earnings; here's what brokerages say
Following the result update, Cadila Healthcare shares fell 1.57% to the intraday low of Rs 389.55 on BSE against the earlier close of Rs 395.95. The stock also hit an intraday high of Rs 401.80 during today's session, after opening at Rs 396 CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to extracts of unaudited financial results of the company for the quarter ended on June 30, 2020. US-led growth helps Cadila post steady Q1 show even as India biz falters
Sales in America, which accounts for 46% of Cadila's consolidated revenues were up 19% over the year ago quarter